 |
Page History
| Excerpt |
|---|
Cancer is a complex category of diseases caused in large part by genetic or genomic, transcriptomic, proteomic, and epigenomics alterations leading to abnormal cell proliferation. Genes and their protein products rarely act in isolation. Therefore, it is necessary to utilize a comprehensive and integrated computational approach informed by systems biology and omics-oriented approaches to investigate the disruption of biological networks caused by genomic alterations. In this talk, Dr. Meerzaman will describe two ongoing projects. The first focuses on Sequencing Quality Control Phase 2 (SEQC II), a collaborative project led by the Food and Drug Administration (FDA) that systematically investigated somatic mutations in paired breast cancer and normal cell lines and formulated best practices for identifying, or calling, genomic variations such as single-nucleotide polymorphisms, copy-number alterations, or single-nucleotide variants. Regarding the second project, Dr. Meerzaman will discuss methods developed by the CGBG team to use mutual exclusivity and pathway network interaction algorithms to identify low-frequency “driver” (that is, causative) genomic alterations at the pathway level.
|
...
